Celiac disease (CD) is an immune-mediated enteropathy triggered by dietary gluten in genetically susceptible individuals, classically expressing HLA-DQ2 and/or HLA-DQ8. After gluten ingestion, deamidated gliadin peptides are presented to T cells, driving both adaptive and innate immune responses in the small intestinal mucosa. The resulting inflammation leads to villous atrophy, crypt hyperplasia, intraepithelial lymphocytosis, and malabsorption. CD is typically confirmed by biopsy of the small intestine, supported by serologic markers such as IgA anti–tissue transglutaminase and anti–endomysial antibodies, and clinical response to a gluten-free diet.
A frequent clinical question is whether early antibiotic exposure might influence subsequent CD risk or whether observed associations reflect confounding factors. Antibiotics can substantially alter the intestinal microbiome by reducing bacterial diversity, shifting community composition, and transiently changing metabolic outputs (including short-chain fatty acid production). Because the gut microbiome participates in immune homeostasis—shaping regulatory T cell differentiation and mucosal barrier integrity—microbiome perturbations are biologically plausible contributors to autoimmune outcomes in genetically primed hosts.
However, epidemiologic studies must carefully disentangle causality from surveillance bias. “Surveillance” refers to differential medical attention that leads to more diagnostic testing, more symptom-driven visits, and therefore more prescriptions. Individuals who later receive a biopsy-confirmed CD diagnosis may have had gastrointestinal symptoms (e.g., chronic diarrhea, abdominal pain, bloating, iron deficiency) before diagnosis. These symptoms can prompt more healthcare contacts and empiric antibiotic use for suspected infectious or inflammatory causes. In such scenarios, antibiotics are not causing CD; rather, they are a marker of heightened symptom-driven clinical evaluation.
This distinction becomes particularly evident when comparing groups with different biopsy findings. If antibiotic use is modestly more common among those with biopsy-confirmed CD than among matched general-population comparators, the difference could reflect a combination of true biological effects and prediagnostic clinical confounding. Yet if the most pronounced antibiotic use occurs in individuals with “normal small intestinal mucosa” (often those undergoing evaluation for symptoms but not meeting histologic criteria for CD), that pattern strongly suggests increased medical surveillance. In other words, a group with negative biopsy results but substantial antibiotic exposure may have been investigated repeatedly for gastrointestinal complaints, leading clinicians to prescribe antibiotics while awaiting definitive diagnosis.
Additionally, the timing of antibiotic exposure matters. Microbiome composition during early life may have disproportionate immunologic impact. Antibiotics administered during infancy or early childhood could theoretically affect maturation of immune tolerance, gut barrier development, and pathogen–commensal balance. Conversely, antibiotic use closer to CD symptom onset may more likely represent reactive treatment of intercurrent infections or empiric management of nonspecific GI symptoms.
Mechanistic hypotheses for a causal role include altered intestinal permeability, increased antigen translocation, and proinflammatory cytokine signaling, alongside reduced regulatory pathways. Antibiotics may also reduce beneficial taxa that promote mucosal barrier function and regulatory immune responses. Still, proving causality requires robust design: longitudinal cohorts with precise medication timing, detailed capture of infection episodes, adjustment for confounders (age, socioeconomic status, healthcare access), and preferably biomarkers of microbiome changes and immune activation.
Clinically, the practical takeaway is that while antibiotics are not routinely recommended for CD prevention, clinicians should recognize that antibiotic exposure patterns may be confounded by symptoms and healthcare utilization. For patients with suspected CD, diagnostic strategies should prioritize appropriate serology and timely biopsy rather than prolonged empiric antimicrobial therapy. For individuals already diagnosed with CD, antimicrobial stewardship remains important: unnecessary antibiotics can worsen diarrhea and disrupt the gut ecosystem, potentially compounding symptoms even when CD is well controlled on a gluten-free diet.
Ongoing research continues to explore how gluten exposure, microbiome ecology, and host genetics interact over time. Future studies using high-resolution metagenomics, metabolomics, and careful temporal modeling will help determine whether there is a real link between antibiotic-induced microbiome disruption and CD initiation, or whether associations mainly reflect diagnostic and treatment behaviors.
Source: Medscape (via the provided source link).
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
